CTLT:NYE-Catalent Inc. (USD)

EQUITY | Drug Manufacturers - Specialty & Generic | New York Stock Exchange

Last Closing

USD 54.65

Change

-0.32 (-0.58)%

Market Cap

USD 3.10B

Volume

1.34M

Analyst Target

USD 102.30
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Catalent Inc is a provider of delivery technologies and development solutions for drugs, biologics and consumer health products. The Company's segments include Oral Technologies, Medication Delivery Solutions and Development & Clinical Services.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-23 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

N/A

USD 80.66B
TAK Takeda Pharmaceutical Co Ltd A..

N/A

USD 42.46B
HLN Haleon plc

N/A

USD 39.18B
TEVA Teva Pharma Industries Ltd ADR

N/A

USD 19.64B
RDY Dr. Reddy’s Laboratories Ltd..

N/A

USD 11.67B
ELAN Elanco Animal Health

N/A

USD 9.03B
PRGO Perrigo Company PLC

N/A

USD 3.85B
PBH Prestige Brand Holdings Inc

N/A

USD 3.33B
EVT Eaton Vance Tax Advantaged Div..

N/A

USD 3.26B
BHC Bausch Health Companies Inc

N/A

USD 2.32B

ETFs Containing CTLT

XPH SPDR® S&P Pharmaceutical.. 4.79 % 0.35 %

N/A

USD 0.20B
IHE iShares U.S. Pharmaceutic.. 4.07 % 0.42 %

N/A

USD 0.69B
BTEC Principal Healthcare Inno.. 2.11 % 0.42 %

N/A

USD 0.03B
2B78:F iShares Healthcare Innova.. 1.78 % 0.00 %

N/A

N/A
HEAL:SW iShares Healthcare Innova.. 1.72 % 0.00 %

N/A

N/A
QUS:AU BetaShares S&P 500 Equal .. 0.28 % 0.00 %

N/A

USD 1.29B
EWSP:SW iShares S&P 500 Equal Wei.. 0.23 % 0.00 %

N/A

USD 1.31B
MNA IQ Merger Arbitrage ETF 0.00 % 0.76 %

N/A

USD 0.26B
PILL Direxion Daily Pharmaceut.. 0.00 % 0.98 %

N/A

USD 0.01B
USLB 0.00 % 0.35 %

N/A

N/A
ACT Enact Holdings Inc 0.00 % 0.75 %

N/A

USD 4.67B
TWOK 0.00 % 0.10 %

N/A

N/A
DRDR:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

USD 1.06B
HEAL:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

USD 1.06B
2B78:XETRA iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

USD 1.14B
MJJ 0.00 % 0.00 %

N/A

N/A
MJO 0.00 % 0.00 %

N/A

N/A
ARB AltShares Trust - AltShar.. 0.00 % 0.00 %

N/A

USD 0.07B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 21.63% 89% A- 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 21.63% 89% A- 91% A-
Trailing 12 Months  
Capital Gain 48.18% 83% B 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 48.18% 83% B 89% A-
Trailing 5 Years  
Capital Gain 18.21% 69% C- 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 18.21% 62% D 43% F
Average Annual (5 Year Horizon)  
Capital Gain 10.23% 75% C 70% C-
Dividend Return 10.23% 75% C 65% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 52.95% 31% F 17% F
Risk Adjusted Return 19.32% 56% F 41% F
Market Capitalization 3.10B 67% D+ 84% B

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 29.10 19% 3%
Price/Book Ratio 2.76 33% 31%
Price / Cash Flow Ratio 38.70 12% 6%
Price/Free Cash Flow Ratio -19.84 89% 93%
Management Effectiveness  
Return on Equity -28.29% 39% 11%
Return on Invested Capital -0.59% 29% 23%
Return on Assets -0.71% 22% 19%
Debt to Equity Ratio 89.99% 38% 40%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector